Endo International plc (NASDAQ:ENDP) (TSE:ENL) – Leerink Swann raised their Q4 2018 earnings per share estimates for Endo International in a research report issued on Monday, April 16th. Leerink Swann analyst A. Fadia now forecasts that the company will post earnings of $0.60 per share for the quarter, up from their previous estimate of $0.56. Leerink Swann has a “Outperform” rating and a $12.00 price objective on the stock. Leerink Swann also issued estimates for Endo International’s FY2022 earnings at $1.75 EPS.
ENDP has been the subject of several other reports. Mizuho cut shares of Endo International from a “buy” rating to a “neutral” rating and cut their price target for the stock from $12.00 to $7.00 in a report on Wednesday, April 4th. BidaskClub cut shares of Endo International from a “sell” rating to a “strong sell” rating in a report on Friday, April 6th. ValuEngine cut shares of Endo International from a “buy” rating to a “hold” rating in a report on Sunday, December 31st. Canaccord Genuity set a $7.00 price target on shares of Endo International and gave the stock a “hold” rating in a report on Wednesday, February 21st. Finally, Barclays cut their price target on shares of Endo International from $15.00 to $10.00 and set an “equal weight” rating for the company in a report on Friday, February 23rd. Four research analysts have rated the stock with a sell rating, sixteen have given a hold rating, three have issued a buy rating and one has assigned a strong buy rating to the company’s stock. The stock currently has an average rating of “Hold” and an average target price of $9.40.
NASDAQ ENDP opened at $5.74 on Wednesday. The stock has a market cap of $1,219.44, a P/E ratio of 1.49 and a beta of 0.38. Endo International has a 52-week low of $5.27 and a 52-week high of $14.15. The company has a debt-to-equity ratio of 17.00, a current ratio of 1.02 and a quick ratio of 0.85.
Endo International (NASDAQ:ENDP) (TSE:ENL) last announced its earnings results on Tuesday, February 27th. The company reported $0.77 EPS for the quarter, beating analysts’ consensus estimates of $0.62 by $0.15. The business had revenue of $768.64 million during the quarter, compared to analysts’ expectations of $762.29 million. Endo International had a negative net margin of 58.68% and a positive return on equity of 81.03%. The business’s revenue was down 38.1% compared to the same quarter last year. During the same period in the prior year, the company earned $1.77 earnings per share.
Institutional investors and hedge funds have recently modified their holdings of the business. Quantitative Investment Management LLC acquired a new stake in shares of Endo International in the fourth quarter valued at approximately $1,569,000. Alps Advisors Inc. grew its position in shares of Endo International by 22.9% in the fourth quarter. Alps Advisors Inc. now owns 307,839 shares of the company’s stock valued at $2,386,000 after purchasing an additional 57,328 shares during the last quarter. River & Mercantile Asset Management LLP grew its position in shares of Endo International by 32.7% in the fourth quarter. River & Mercantile Asset Management LLP now owns 475,650 shares of the company’s stock valued at $3,679,000 after purchasing an additional 117,110 shares during the last quarter. Hunter Associates Investment Management LLC grew its position in shares of Endo International by 53.7% in the fourth quarter. Hunter Associates Investment Management LLC now owns 67,150 shares of the company’s stock valued at $520,000 after purchasing an additional 23,450 shares during the last quarter. Finally, Systematic Financial Management LP grew its position in shares of Endo International by 22.5% in the fourth quarter. Systematic Financial Management LP now owns 190,550 shares of the company’s stock valued at $1,477,000 after purchasing an additional 35,045 shares during the last quarter. Institutional investors own 94.77% of the company’s stock.
TRADEMARK VIOLATION NOTICE: This article was originally reported by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are accessing this article on another website, it was illegally copied and republished in violation of U.S. and international copyright and trademark law. The original version of this article can be accessed at https://www.dispatchtribunal.com/2018/04/19/endo-international-plc-expected-to-post-q4-2018-earnings-of-0-60-per-share-endp.html.
Endo International Company Profile
Endo International plc, a specialty pharmaceutical company, manufactures and sells generic and branded pharmaceuticals in the United States, Canada, and internationally. The company operates through three segments: U.S. Generic Pharmaceuticals, U.S. Branded Pharmaceuticals, and International Pharmaceuticals.
Receive News & Ratings for Endo International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Endo International and related companies with MarketBeat.com's FREE daily email newsletter.